4 - 7 June 2025

Reduced kidney function decline with semaglutide across kidney risk categories: analyses from the FLOW trial

Authors :

David Cherney1; Nicolas Belmar2; Trine Welløv Boesgaard2; Julie Funch Furberg2; Thomas Idorn2; Kenneth W. Mahaffey3; Johannes F. E. Mann4,5; Vlado Perkovic6; Richard E. Pratley7; Katherine R. Tuttle8,9; Peter Rossing10

Affiliations
View Details Hide Details
{{ getPageNum(PDFPage) }}
Keywords
Chronic Kidney Disease
Congress oral presentation
GLP-1 RA
Semaglutide
PHASE 3 (RCT)